{"id":"restylane-l","_chembl":{"chemblId":"CHEMBL58832","moleculeType":"Small molecule","molecularWeight":"132.12"},"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Restylane-L®","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T06:32:39.397524+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T06:33:36.488010+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T06:32:45.004952+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL58832/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T06:33:16.473422+00:00"}},"_dailymed":null,"aiSummary":"Restylane-L® is a marketed product developed by the University of Pennsylvania, positioned in the dermatological aesthetics market. The key composition patent expires in 2028, providing a strong barrier to generic competition until then. The primary risk is the lack of revenue data and key trial results, which may limit strategic planning and investor confidence.","_scrapedAt":"2026-03-28T00:04:45.235Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T06:33:36.488096+00:00","fieldsConflicting":0,"overallConfidence":0.95},"trialDetails":[{"nctId":"NCT04540913","phase":"","title":"RHA® 3 Versus Restylane-L® for Lip Augmentation","status":"COMPLETED","sponsor":"Teoxane SA","startDate":"2020-10-22","conditions":"Lip Augmentation, Lip","enrollment":202},{"nctId":"NCT03460158","phase":"PHASE4","title":"Prospective Evaluation of Facial Cosmetic Procedures","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2020-08-21","conditions":"Cosmetic Techniques","enrollment":101},{"nctId":"NCT04154930","phase":"NA","title":"Restylane-L for Correction of Infraorbital Hollows","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2019-11-11","conditions":"Infraorbital Hollows","enrollment":333},{"nctId":"NCT04861766","phase":"NA","title":"Safety and Effectiveness of STYLAGE® L for Correction of Moderate and Severe Nasolabial Folds in Chinese Adults","status":"COMPLETED","sponsor":"Laboratoires Vivacy","startDate":"2021-05-06","conditions":"Aging, Skin Wrinkling","enrollment":390},{"nctId":"NCT04169308","phase":"PHASE1","title":"Effects of Restylane-L® Filler Injection for Non-Surgical Rhinoplasty","status":"COMPLETED","sponsor":"DeNova Research","startDate":"2019-01-01","conditions":"Deformity of Nasal Cartilage","enrollment":10},{"nctId":"NCT01998581","phase":"NA","title":"A Safety and Effectiveness Study of JUVÉDERM VOLBELLA® XC Injectable Gel for Lip and Perioral Enhancement","status":"COMPLETED","sponsor":"Allergan","startDate":"2013-11-01","conditions":"Subjects Desiring Lip Augmentation","enrollment":225},{"nctId":"NCT01579305","phase":"NA","title":"Safety and Effectiveness of Juvéderm® Volbella With Lidocaine Versus Restylane-L® for Lip Volume Enhancement","status":"COMPLETED","sponsor":"Allergan Medical","startDate":"2012-04","conditions":"Lip Volume Enhancement","enrollment":285},{"nctId":"NCT02751034","phase":"PHASE3","title":"Efficacy and Safety Evaluation Study of Neuramis® Deep Lidocaine in Correction of Nasolabial Fold","status":"COMPLETED","sponsor":"Medy-Tox","startDate":"2013-06","conditions":"Nasolabial Fold","enrollment":60},{"nctId":"NCT00797459","phase":"NA","title":"Safety & Tolerability Study That Compares Restylane to Restylane With Lidocaine While Correcting Wrinkles in the Nasolabial Folds","status":"COMPLETED","sponsor":"Medicis Global Service Corporation","startDate":"2008-11","conditions":"Nasolabial Folds","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"crossReferences":{"chemblId":"CHEMBL58832"},"_approvalHistory":[],"publicationCount":16,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Hyaluronic acid gel"],"phase":"marketed","status":"active","brandName":"Restylane-L®","genericName":"Restylane-L®","companyName":"University of Pennsylvania","companyId":"university-of-pennsylvania","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":3,"withResults":3},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T06:33:36.488096+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"enriching","dataCompleteness":{"mechanism":false,"indications":false,"safety":false,"trials":true,"score":1}}